Moderna Swings to $162M Q3 Profit, Raises 2026 Revenue Growth Outlook to 15%-25%
MRNA has more than doubled off its 52-week low of $22.28.
Summary
Moderna posted $162 million of Q3 net income ($0.38 diluted EPS) on $1.3 billion of revenue, up 29%, and raised 2026 revenue growth guidance to 15%-25% while lifting its year-end cash outlook to $8.1-$8.3 billion.
Key Events · Earnings and Guidance · MRNA
-
Q3 Swing to Profitability
Net income was $162 million, or $0.38 per diluted share, versus a $(200) million net loss and $(0.51) per share in Q3 2025, a $362 million year-over-year improvement.
-
Revenue Up 29% to $1.3 Billion
Total revenue rose to $1.3 billion from $1.0 billion, with $780 million in the U.S. and $533 million international, driven by higher COVID vaccine sales under government partnerships.
-
2026 Guidance Raised
Full-year revenue growth outlook lifted to 15%-25% from up to 10%; R&D trimmed to about $2.7 billion from about $2.9 billion, roughly $0.2 billion of operating expense improvement.
-
Year-End Cash Outlook Jumps
Cash and investments are now expected at $8.1-$8.3 billion versus the prior $4.7-$5.2 billion outlook, reflecting the $2.6 billion net convertible note proceeds and better operations; Q3 cash stood at $8.0 billion.
Analysis · MRNA · Life Sciences
A year after posting a $(200) million loss, Moderna delivered $162 million of net income on $1.3 billion of revenue, up 29%, and lifted full-year revenue growth guidance to 15%-25% from up to 10%. The R&D budget was trimmed to about $2.7 billion, and the company now expects to end 2026 with $8.1-$8.3 billion of cash, up sharply from the prior $4.7-$5.2 billion outlook, helped by the $2.6 billion net raised from convertible notes. For a company that was burning cash and carrying a going-concern-adjacent narrative a year ago, the combination of profitability, a higher revenue trajectory and a much larger cash cushion changes the near-term funding picture. The GSK settlement on October 28 removes a litigation overhang with no payment required.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MRNA was trading at $252.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $96.4B. The 52-week trading range was $22.28 to $261.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.